SARS-CoV-2 is a strain of coronaviruses that was introduced to human populations from an animal source in the Chinese province of Hubei in late 2019. The spread of infection has since been driven by human-to-human transmission. Efficient medical countermeasures to block the progress of a disease, about which little is known, are central to global health.
IBIO-201 is a COVID-19 vaccine candidate based on a subunit platform that combines antigens derived from the SARS-CoV-2 spike protein fused with iBio’s patented LicKM booster molecule to enhance immune response. iBio’s proprietary LicKM technology offers the potential to strengthen the initial immune response to the antigen and extend the duration of the immune response, possibly lowering vaccine antigen dose requirements or enabling fewer doses to establish prolonged immunity. Fusing the SARS-CoV-2 spike protein antigens with iBio’s LicKM technology may be advantageous in achieving prolonged immune response against COVID-19.
IBIO-201 has entered preclinical studies for the evaluation of immune response in mice.